Melane Sampson, Author at BioTuesdays

Developments

111, Inc., Jianming Pharma to develop chronic disease management platform in China

111, Inc. (NASDAQ:YI), a leading digital healthcare platform company in China, and Jianming Pharmaceutical Group signed a strategic cooperation agreement to develop an online chronic disease management platform for the...

March 25, 2021

Executive Moves

Oppenheimer expands healthcare investment banking team

Oppenheimer (NYSE:OPY) continued to build out its healthcare leadership team, adding three members to its healthcare investment banking team: Jonathan Fassberg, in the newly created role of vice chairman; Brian Korb, as...

March 24, 2021

Developments

Lineage presents additional interim data with OpRegen in dry AMD with GA

Lineage Cell Therapeutics (NYSE American, TASE:LCTX) presented new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen, for the treatment of dry age...

March 23, 2021

Developments

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) and ENDRA Life Sciences (NASDAQ:NDRA) signed a collaboration agreement to incorporate ENDRA’s Thermo Acoustic Enhanced UltraSound (TAEUS) as an add-on technology to support...

March 18, 2021

Developments

111, Inc. in strategic partnership with BeiGene

111, Inc. (NASDAQ:YI), a leading digital healthcare platform in China, entered into a strategic cooperation agreement with BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage and development biotechnology company...

March 17, 2021

Markets

BTIG starts Seelos Therapeutics at buy; PT $14

BTIG initiated coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $14 price target. The stock closed at $3.04 on March 11. Seelos’ lead clinical candidate, SLS-002, is an intranasally delivered...

March 12, 2021

Developments

Coridea, Deerfield to accelerate medtech innovation at NYC site

Coridea and Deerfield Management have established Deerfield Device Design and Development Catalyst to advance medtech innovation and accelerate the formation of commercial companies. Coridea is a medtech incubator;...

March 9, 2021

Executive Moves

KA Imaging adds world renowned radiologist Philip Templeton as CMO

X-ray manufacturer, KA Imaging, appointed Dr. Philip Templeton, M.D., to the newly created position of chief medical officer (CMO). A board certified radiologist, Dr. Templeton brings over 38 years of academic and...

March 8, 2021

Markets

Cantor starts Akebia Therapeutics at OW; PT $8

Cantor Fitzgerald launched coverage of Akebia Therapeutics (NASDAQ:AKBA) with an “overweight” rating and $8 price target. The stock closed at $3.41 on March 5. The company’s lead asset, vadadustat, is an oral hypoxia...

March 8, 2021

Developments

Azura Ophthalmics posts positive Phase 2 results in Meibomian gland dysfunction

Closely held Azura Ophthalmics of Israel announced positive topline results from a Phase 2 program evaluating the company’s investigational therapy for the treatment of Meibomian gland dysfunction (MGD). The company’s...

March 5, 2021

Author - Melane Sampson

111, Inc., Jianming Pharma to develop chronic disease management platform in China

Oppenheimer expands healthcare investment banking team

Lineage presents additional interim data with OpRegen in dry AMD with GA

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

111, Inc. in strategic partnership with BeiGene

BTIG starts Seelos Therapeutics at buy; PT $14

Coridea, Deerfield to accelerate medtech innovation at NYC site

KA Imaging adds world renowned radiologist Philip Templeton as CMO

Cantor starts Akebia Therapeutics at OW; PT $8

Azura Ophthalmics posts positive Phase 2 results in Meibomian gland dysfunction

Subscribe